The tweet was deleted by the author.
But we saved everything 🙂.
Ceribell, Inc. has introduced the first and only FDA-cleared device designed for bedside diagnosis of electrographic status epilepticus and monitoring of delirium in adults.
This new bedside monitor aims to assist clinicians in providing rapid, accurate neurological assessments for critical care patients. The device is presented as an innovation that unifies two vital brain function applications into a single platform, potentially enhancing clinical workflow and patient outcomes. The announcement was made at #ADS2026, signaling the company's commitment to advancing neurological monitoring technology.
Ceribell has previously called for rapid EEG adoption to detect silent seizures in high-acuity patients and prevent irreversible harm, according to an earlier report on urgent seizure detection. The company continues to focus on bedside technologies that support neurological assessments in critical care. This development follows its prior initiatives aimed at addressing gaps in seizure identification.